JNJ-87562761

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-87562761, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]